• Michael M C Wong, Albert K K Chung, Timothy M H Yeung, Wong David T W DTW Asian Association of Neuropsychopharmacology., C K Lee, Eric Lai, Gloria F Y Chan, Gregory K L Mak, Jessica O Y Wong, Roger M K Ng, K L Tam, and K Y Mak.
• Asian Association of Neuropsychopharmacology.
• Intern Med J. 2020 Sep 1; 50 Suppl 3: 6-14.

AbstractAripiprazole, a dopamine partial agonist, is a second-generation anti-psychotic that is widely used for the treatment of schizophrenia and other psychotic disorders. A group of psychiatric experts in Hong Kong developed a set of consensus statements, aiming to facilitate the understanding of clinical properties and usages of aripiprazole among local physicians. Of note, because aripiprazole long-acting injectable has been available locally not long before the establishment of the consensus panel, which limited the discussion on its use in the local context, the consensus statements were focused primarily on oral aripiprazole. To draft the consensus statements, the panellists discussed the published evidence and their clinical experience regarding aripiprazole in a series of meetings based on several areas. At the final meeting, each drafted statement was voted on anonymously by all panellists based on its practicability of recommendation in Hong Kong. A set of consensus statements on the characteristics and clinical use of aripiprazole was established and accepted by the panel. These statements serve to provide a practical reference for physicians in Hong Kong, and possibly other parts of the Asia-Pacific region, on the use of aripiprazole in people with schizophrenia spectrum disorders and other psychotic problems.© 2020 Royal Australasian College of Physicians.

12 keywords...

hide…